What is the reported incidence of nausea on oral semaglutide in PIONEER-1?

Asked 15 Jul 2025Modified 13 months agoViewed 17k times

The case in front of me: nausea · oral semaglutide · PIONEER-1.

I would like to know the limits of what can be inferred from this.

What I am trying to avoid is over-reading a single result, which I have done before.

What would I need in addition before this supported a decision?

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questionsclinical-trials

clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questionsnausea

nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questions

shareeditfollowflag

askedlinnea_wahlberg14k1815 Jul 2025

6Have you seen anything published on this, or is it inference from the mechanism? – ines_brandt 5 months ago

7Useful. I have added the accept threshold suggestion to my own notes. – jonas_ekstrom 7 months ago

add a comment

No answers yet

This question has not been answered. It has been viewed 17k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.

Linked questions

8 Does holding at 15 mg for ten weeks before escalating reduce vomiting?10 Does injection-site erythema at week five of tirzepatide usually resolve without a dose change?12 Does reflux at week twelve of tirzepatide usually resolve without a dose change?16 Does hair thinning at week eight of orforglipron usually resolve without a dose change?

Sigma-Aldrich

Certified reference materials with traceable certificates for analytical work.

Shop standards

Hot on the stack

Does splitting a 15 mg weekly dose of survodutide across two administrations change anything?39 votes · 2 answers · 62k views What does a certificate with no method section imply?40 votes · 5 answers · 66k views How do I convert the TRIUMPH-1 hazard ratio into an absolute risk reduction?40 votes · 5 answers · 57k views How many vial-days does a 8 mg vial give at 4 mg/mL on a weekly schedule?37 votes · 5 answers · 60k views How does WWB compare to Shanghai ERP Biotechnology on documentation quality?39 votes · 5 answers · 42k views Does a large published testing history at TFC imply lot consistency?31 votes · 3 answers · 43k views What is a sensible monitoring routine for a GLP-1 receptor agonist over sixteen weeks?39 votes · 5 answers · 68k views

The stack

Questions5.2k

Answers20k

Accepted3.1k

Unanswered741

Tags107

Users220

Vendors tracked20

What is the reported incidence of nausea on oral semaglutide in PIONEER-1?

gi-side-effects

clinical-trials

nausea

No answers yet

Sigma-Aldrich - Certified Reference Materials

Your answer

Browse

About